CTOs on the Move

Correlogic Systems

www.correlogic.com

 
Correlogic Systems is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.correlogic.com
  • 20271 Goldenrod Ln Ste 2070
    Germantown, MD USA 20876
  • Phone: 301.795.1700

Executives

Name Title Contact Details

Similar Companies

Advanced Life Sciences

Advanced Life Sciences is a Woodridge, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Moderna

Learn how we’re changing the world of medicine. Discover career opportunities, our product pipeline, and browse media resources. Meet Moderna.

SignalChem Lifesciences

SignalChem Lifesciences Corporation is a privately owned biopharmaceutical company specializing in the discovery and development of kinase inhibitors as innovative therapies for cancer, inflammation and neurological diseases.   The Company has a robust kinase platform encompassing 450 kinase targets and assays for the development and commercialization of unique therapies in many diseases.   This vast resource empowers SLC’s scientists to identify novel drug candidates against kinase targets of interest.   Another key part of SLC’s kinase drug development platform is KineCore, a kinase focused small molecule library that was designed and assembled in-house.

ARCA biopharma

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.

Day One Biopharmaceuticals

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.